The need for a blueprint emergency plan to avoid a HPAPI crisis

SMi Group21 - 22 October 2019, Boston, USA.
With a massive growth within the HPAPI market, manufacturers cannot afford to be complacent in terms of staff training, utilization of approved technology and blueprint accident plans. Straying away from the correct procedures can have a massive affect on your business and industry.

At the inaugural HPAPI USA conference, these issues will be discussed and give delegates the opportunity to hear from industry experts who will share their experiences and arm attendees with the safety strategies to implement into their organization.

Ayasha Ovals from Taro Pharmaceuticals will provide a keynote address on Day One of the conference, where she will give insights into emergency procedures for HPAPI disasters and how to manage an accident, including long term cost savings, managing risk, fail-safe procedure and forward planning.

Industrial hygiene and potent compound containment will be discussed by Joseph Grill, former Associate Director from Purdue Pharma, where he will share insights on common pitfalls in industrial hygiene, flexible containment and the potential of hastening R&D.

Sakari Consultants, President & Principle, Patricia Weidemanwill focus on training and managing workers with HPAPI exposure, along with the best available techniques for cleaning and waste management. She will also look at technological innovations for containment and transfer technologies, ensuring staff are sufficiently trained and ensure they understand the equipment they are utilising.

The programme with full speaker line-up is available to download at www.hpapi-usa.com

Plus, two HPAPI USA Post Conference Workshops will take place in Boston on October 23rd:

Workshop A: The roadmap from assessing HPAPI hazards to containment implementation along with CDMO dynamics hosted byDr Janet Gould, Principal Toxicologist, SafeBridge Consultants and Charlyn Reihamn, Principle Occupational Health Consultant,SafeBridge Consultants

Workshop B: How to sell your containment project to management: financial justification for containment solutions hosted by DrDavid Eherts, Vice President Global EHS, Allergan Inc

For those interested, an early bird saving of $300 is available for conference tickets booked before Friday 28th June. Register online at www.hpapi-usa.com

Sponsoredby BSP Pharmaceuticals, LONZA, Minakem, SafeBridge Consultants

For delegate enquiries, please contact Fateja Begum on +44 (0)20 7827 6184 or This email address is being protected from spambots. You need JavaScript enabled to view it.

For sponsorship, exhibition and branding enquiries, please contact Alia Malick on +44 (0)20 7827 6168 or This email address is being protected from spambots. You need JavaScript enabled to view it.

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 This email address is being protected from spambots. You need JavaScript enabled to view it.

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...